Evidence mapPaperPMID 32845968Full record

Trial reportThe Journal of clinical endocrinology and metabolism2020

Long-term Change in Physiological Markers and Cognitive Performance in Type 2 Diabetes: The Look AHEAD Study.

Owen T Carmichael, Rebecca H Neiberg, Gareth R Dutton, Kathleen M Hayden, Edward Horton, F Xavier Pi-Sunyer, Karen C Johnson, Stephen R Rapp, Adam P Spira, Mark A Espeland

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Does lifestyle intervention lower clinically significant cognitive impairment risk?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Triglyceride Glucose Index is Related with the Risk of Mild Cognitive Impairment in Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Owen T CarmichaelBiomedical Imaging Center, Pennington Biomedical Research Center, Baton Rouge, Louisiana.
Rebecca H NeibergDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Gareth R DuttonDepartment of Medicine, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Kathleen M HaydenSocial Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Edward HortonJoslin Diabetes Center, Harvard University, Boston, Massachusetts.
F Xavier Pi-SunyerDivision of Endocrinology, Obesity/Nutrition Research Center, Columbia University College of Physicians and Surgeons, New York, NY.
Karen C JohnsonDepartment of Preventive Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee.
Stephen R RappDepartment of Psychiatry & Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Adam P SpiraDepartment of Mental Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
Mark A EspelandDivision of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · UNIVERSITY OF COLORADO DENVER · 1985 to 2005
$37.2M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1985 to 2005
$27.6M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · MASSACHUSETTS GENERAL HOSPITAL · 1985 to 2005
$26.1M
HEALTH OUTCOMES OF WEIGHT-LOSS: DATA COORDINATING CENTERU01DK057136 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 1999 to 2005
$18.5M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · JOHNS HOPKINS UNIVERSITY · 1986 to 2005
$16.4M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · 1985 to 2005
$16.1M
Clinical Center for Look AHEAD: Health in DiabetesU01DK057178 · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · 1999 to 2005
$9.3M
Clinical Center for Look AHEAD: Health in DiabetesU01DK057151 · UNIVERSITY OF COLORADO DENVER · 1999 to 2005
$8.4M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW)U01DK057135 · UNIVERSITY OF PENNSYLVANIA · 1999 to 2005
$8.2M
SHOW PROJECTU01DK057154 · MASSACHUSETTS GENERAL HOSPITAL · 1999 to 2005
$8.1M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW) TRIALU01DK056992 · MIRIAM HOSPITAL · 1999 to 2005
$8.1M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW) TRIALU01DK057177 · BAYLOR COLLEGE OF MEDICINE · 1999 to 2005
$7.7M
NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR001346NCRR NIH HHS M01 RR002719NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1 RR025758NIA NIH HHS P30 AG049638NIDDK NIH HHS P30 DK046204NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK079626NIDDK NIH HHS U01 DK056990NIDDK NIH HHS U01 DK056992NIDDK NIH HHS U01 DK057002NIDDK NIH HHS U01 DK057008NIDDK NIH HHS U01 DK057078NIDDK NIH HHS U01 DK057131NIDDK NIH HHS U01 DK057135NIDDK NIH HHS U01 DK057136NIDDK NIH HHS U01 DK057149NIDDK NIH HHS U01 DK057151NIDDK NIH HHS U01 DK057154NIDDK NIH HHS U01 DK057171NIDDK NIH HHS U01 DK057177NIDDK NIH HHS U01 DK057178NIDDK NIH HHS U01 DK057182NIDDK NIH HHS U01 DK057219
6 · The paper itself

Abstract

contextThe effects of physiological improvements on cognitive function among persons with type 2 diabetes mellitus (T2DM) are not fully understood.

objectiveTo determine whether improvements in physiological markers (body weight, blood sugar control, and physical activity) during intensive lifestyle intervention (ILI) are associated with enhancements in cognitive function in older adults with T2DM.

designMultisite randomized controlled trial.

settingAcademic research centers. PATIENTS OR OTHER

participantsParticipants were aged 45-76 years, with T2DM.

interventionThe Action for Health in Diabetes (Look AHEAD) study, a randomized, controlled clinical trial of ILI.

main outcome measureTwo to 3 cognitive assessments were collected from 1089 participants, the first and last occurring a mean (standard deviation) of 8.6 (1.0) and 11.5 (0.7) years after enrollment.

resultsGreater improvement in blood sugar control was associated with better cognitive scores (fasting glucose and Rey Auditory Verbal Learning Test [AVLT]: P = 0.0148; fasting glucose and Digit Symbol Coding (DSC): P = 0.0360; HbA1C and DSC: P = 0.0477); but weight loss had mixed associations with cognitive scores (greater body mass index [BMI] reduction and worse AVLT overall: P = 0.0053; and greater BMI reduction and better DSC scores among those overweight but not obese at baseline: P = 0.010). Associations were strongest among those who were overweight (not obese) at baseline, and among those with a history of cardiovascular disease (CVD) at baseline.

conclusionsImprovements in glycemic control, but not necessarily weight status, during ILI may be associated with better subsequent cognitive performance. These associations may differ by adiposity and CVD history.

Indexed as

BiomarkersAdiposityAgedBody WeightCognitionCognition DisordersDiabetes Mellitus, Type 2ExerciseFemaleFollow-Up StudiesGlycemic ControlHumansLife StyleMaleMiddle AgedRisk Reduction BehaviorBiomarkerscognitive functionglycemic controllifestyle interventionphysical activitytype 2 diabetesweight loss

Identifiers

PMID32845968
PMCPMC7566388

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.